,condition,gene,fold,percent,cell type,pathway
1,ALS_A,NF1,0.7,36,smooth,pyruvate metabolism
2,ALS_A,UEVLD,0.2,96,skeletal,Wnt signalling
3,ALS_A,CDC37L1,0.7,89,skeletal,cancer pathways
4,ALS_A,HOXD10,-0.1,54,cardiac,pyruvate metabolism
5,ALS_A,NNT,-0.1,33,smooth,apoptosis
6,ALS_A,HUWE1,0.5,54,cardiac,Wnt signalling
7,ALS_A,GJA5,NA,58,skeletal,propanoate metabolism
8,ALS_A,SPCS3,0.6,14,cardiac,Wnt signalling
9,ALS_A,DOT1L,-0.2,37,skeletal,Wnt signalling
10,ALS_A,ATP6V0E1,NA,27,cardiac,Wnt signalling
11,ALS_A,XAF1,-0.2,100,cardiac,cancer pathways
12,ALS_A,MAFG,-0.8,64,smooth,MAPK
13,ALS_A,AAK1,NA,3,cardiac,MAPK
14,ALS_A,TM2D3,0.5,36,skeletal,Wnt signalling
15,ALS_A,SSR3,0.1,18,cardiac,focal adhesion
16,ALS_A,ZNF281,-0.3,36,skeletal,propanoate metabolism
17,ALS_A,JAM2,0.2,56,skeletal,synthesis and degradation of ketone bodies
18,ALS_A,CDC23,0.5,47,smooth,MAPK
19,ALS_A,PLN,-0.6,67,smooth,synthesis and degradation of ketone bodies
20,ALS_A,PGP,-0.2,89,skeletal,citrate cycle
21,ALS_A,HYI,-0.2,12,cardiac,citrate cycle
22,ALS_A,IMPACT,0.3,89,smooth,apoptosis
23,ALS_A,C2orf49,0.2,9,skeletal,cancer pathways
24,ALS_A,HDAC11,-0.3,85,skeletal,pyruvate metabolism
25,ALS_A,CCN4,-0.3,68,skeletal,Wnt signalling
26,ALS_A,MKLN1,0.1,86,smooth,synthesis and degradation of ketone bodies
27,ALS_A,GPRC5B,0.3,4,skeletal,fatty acid degradation
28,ALS_A,RPS6KB1,0.3,48,smooth,pyruvate metabolism
29,ALS_A,PSMA3,0.6,70,skeletal,cancer pathways
30,ALS_A,JARID2,-0.1,92,skeletal,fatty acid degradation
31,ALS_A,ODF2,-0.3,76,smooth,pyruvate metabolism
32,ALS_A,MON2,0.3,69,smooth,Wnt signalling
33,ALS_A,PDLIM2,-0.4,1,skeletal,cancer pathways
34,ALS_A,WAC,0.7,19,skeletal,fatty acid degradation
35,ALS_A,FLCN,NA,3,smooth,synthesis and degradation of ketone bodies
36,ALS_A,ATF6,-0.1,94,smooth,propanoate metabolism
37,ALS_A,TRAFD1,NA,28,cardiac,fatty acid degradation
38,ALS_A,BICD1,-0.2,51,skeletal,apoptosis
39,ALS_A,ANP32A,0.6,12,smooth,Wnt signalling
40,ALS_A,KDSR,NA,52,smooth,MAPK
41,ALS_A,FBXO9,0.3,80,smooth,propanoate metabolism
42,ALS_A,UBQLN2,1.1,28,cardiac,synthesis and degradation of ketone bodies
43,ALS_A,ZFX,NA,94,skeletal,cancer pathways
44,ALS_A,CPLX2,-0.3,69,skeletal,apoptosis
45,ALS_A,CLPX,0.3,3,cardiac,cancer pathways
46,ALS_A,SGCB,0.2,37,cardiac,propanoate metabolism
47,ALS_A,SEMA5A,-0.2,42,cardiac,cancer pathways
48,ALS_A,PTPRB,NA,74,smooth,focal adhesion
49,ALS_A,TMEM33,0.4,97,smooth,pyruvate metabolism
50,ALS_A,SMC1A,0.4,28,cardiac,MAPK
51,AQM_A,NF1,0.6,75,smooth,citrate cycle
52,AQM_A,UEVLD,0.3,61,skeletal,focal adhesion
53,AQM_A,CDC37L1,0.5,21,cardiac,focal adhesion
54,AQM_A,HOXD10,-0.6,51,cardiac,synthesis and degradation of ketone bodies
55,AQM_A,NNT,-0.6,82,cardiac,focal adhesion
56,AQM_A,HUWE1,0.8,70,cardiac,citrate cycle
57,AQM_A,GJA5,-0.1,80,skeletal,MAPK
58,AQM_A,SPCS3,0.5,13,smooth,apoptosis
59,AQM_A,DOT1L,-0.4,31,smooth,apoptosis
60,AQM_A,ATP6V0E1,0.5,94,cardiac,apoptosis
61,AQM_A,XAF1,-0.2,76,skeletal,fatty acid degradation
62,AQM_A,MAFG,NA,31,skeletal,propanoate metabolism
63,AQM_A,AAK1,0.7,98,skeletal,focal adhesion
64,AQM_A,TM2D3,0.9,7,skeletal,apoptosis
65,AQM_A,SSR3,NA,8,cardiac,fatty acid degradation
66,AQM_A,ZNF281,-0.2,19,skeletal,Wnt signalling
67,AQM_A,JAM2,-0.1,19,cardiac,propanoate metabolism
68,AQM_A,CDC23,0.6,64,smooth,apoptosis
69,AQM_A,PLN,-2,87,skeletal,apoptosis
70,AQM_A,PGP,-0.4,74,smooth,fatty acid degradation
71,AQM_A,HYI,-0.1,49,skeletal,MAPK
72,AQM_A,IMPACT,0.4,44,skeletal,citrate cycle
73,AQM_A,C2orf49,-0.1,37,skeletal,citrate cycle
74,AQM_A,HDAC11,-0.5,78,smooth,fatty acid degradation
75,AQM_A,CCN4,-0.3,24,cardiac,cancer pathways
76,AQM_A,MKLN1,0.7,75,smooth,apoptosis
77,AQM_A,GPRC5B,0.1,48,skeletal,focal adhesion
78,AQM_A,RPS6KB1,0.7,7,smooth,synthesis and degradation of ketone bodies
79,AQM_A,PSMA3,0.6,66,smooth,MAPK
80,AQM_A,JARID2,-0.2,76,skeletal,propanoate metabolism
81,AQM_A,ODF2,-0.1,98,smooth,Wnt signalling
82,AQM_A,MON2,0.7,26,cardiac,cancer pathways
83,AQM_A,PDLIM2,-1.1,57,skeletal,pyruvate metabolism
84,AQM_A,WAC,0.8,85,smooth,propanoate metabolism
85,AQM_A,FLCN,0.2,100,cardiac,fatty acid degradation
86,AQM_A,ATF6,0.2,31,cardiac,Wnt signalling
87,AQM_A,TRAFD1,-0.1,13,smooth,fatty acid degradation
88,AQM_A,BICD1,-0.3,57,skeletal,focal adhesion
89,AQM_A,ANP32A,0.5,53,skeletal,cancer pathways
90,AQM_A,KDSR,0.3,71,smooth,Wnt signalling
91,AQM_A,FBXO9,NA,8,smooth,pyruvate metabolism
92,AQM_A,UBQLN2,0.7,85,skeletal,propanoate metabolism
93,AQM_A,ZFX,-0.1,36,smooth,propanoate metabolism
94,AQM_A,CPLX2,-0.3,11,skeletal,fatty acid degradation
95,AQM_A,CLPX,0.3,73,smooth,propanoate metabolism
96,AQM_A,SGCB,0.3,60,smooth,fatty acid degradation
97,AQM_A,SEMA5A,-0.4,20,smooth,MAPK
98,AQM_A,PTPRB,-0.6,66,skeletal,cancer pathways
99,AQM_A,TMEM33,0.6,21,smooth,Wnt signalling
100,AQM_A,SMC1A,2.5,25,cardiac,fatty acid degradation
101,BMD_A,NF1,0.1,51,cardiac,cancer pathways
102,BMD_A,UEVLD,-0.1,63,smooth,citrate cycle
103,BMD_A,CDC37L1,NA,55,cardiac,MAPK
104,BMD_A,HOXD10,0.1,25,skeletal,pyruvate metabolism
105,BMD_A,NNT,-0.2,79,cardiac,citrate cycle
106,BMD_A,HUWE1,0.1,37,cardiac,apoptosis
107,BMD_A,GJA5,NA,23,skeletal,focal adhesion
108,BMD_A,SPCS3,0.6,40,smooth,fatty acid degradation
109,BMD_A,DOT1L,0.1,87,smooth,pyruvate metabolism
110,BMD_A,ATP6V0E1,0.4,16,skeletal,propanoate metabolism
111,BMD_A,XAF1,-0.1,8,smooth,synthesis and degradation of ketone bodies
112,BMD_A,MAFG,-0.2,8,cardiac,focal adhesion
113,BMD_A,AAK1,0.2,67,skeletal,apoptosis
114,BMD_A,TM2D3,0.1,45,skeletal,Wnt signalling
115,BMD_A,SSR3,NA,21,skeletal,synthesis and degradation of ketone bodies
116,BMD_A,ZNF281,-0.2,29,cardiac,cancer pathways
117,BMD_A,JAM2,0.3,56,skeletal,apoptosis
118,BMD_A,CDC23,0.1,15,cardiac,Wnt signalling
119,BMD_A,PLN,-0.7,86,smooth,synthesis and degradation of ketone bodies
120,BMD_A,PGP,0.2,78,skeletal,MAPK
121,BMD_A,HYI,NA,34,smooth,synthesis and degradation of ketone bodies
122,BMD_A,IMPACT,NA,24,smooth,synthesis and degradation of ketone bodies
123,BMD_A,C2orf49,-0.2,76,skeletal,Wnt signalling
124,BMD_A,HDAC11,NA,70,skeletal,apoptosis
125,BMD_A,CCN4,-0.3,87,smooth,synthesis and degradation of ketone bodies
126,BMD_A,MKLN1,NA,88,cardiac,cancer pathways
127,BMD_A,GPRC5B,NA,92,skeletal,pyruvate metabolism
128,BMD_A,RPS6KB1,-0.2,53,smooth,fatty acid degradation
129,BMD_A,PSMA3,-0.2,5,smooth,cancer pathways
130,BMD_A,JARID2,0.2,2,cardiac,Wnt signalling
131,BMD_A,ODF2,-0.1,15,skeletal,MAPK
132,BMD_A,MON2,-0.4,14,skeletal,Wnt signalling
133,BMD_A,PDLIM2,-0.5,36,cardiac,propanoate metabolism
134,BMD_A,WAC,-0.1,91,skeletal,propanoate metabolism
135,BMD_A,FLCN,NA,93,skeletal,apoptosis
136,BMD_A,ATF6,NA,4,skeletal,citrate cycle
137,BMD_A,TRAFD1,0.2,10,skeletal,focal adhesion
138,BMD_A,BICD1,NA,72,cardiac,cancer pathways
139,BMD_A,ANP32A,0.1,13,cardiac,synthesis and degradation of ketone bodies
140,BMD_A,KDSR,-0.4,36,cardiac,synthesis and degradation of ketone bodies
141,BMD_A,FBXO9,NA,63,skeletal,synthesis and degradation of ketone bodies
142,BMD_A,UBQLN2,0.1,95,skeletal,pyruvate metabolism
143,BMD_A,ZFX,-0.2,55,cardiac,synthesis and degradation of ketone bodies
144,BMD_A,CPLX2,0.1,20,smooth,synthesis and degradation of ketone bodies
145,BMD_A,CLPX,-0.1,95,skeletal,citrate cycle
146,BMD_A,SGCB,-0.1,52,cardiac,synthesis and degradation of ketone bodies
147,BMD_A,SEMA5A,-0.1,37,cardiac,synthesis and degradation of ketone bodies
148,BMD_A,PTPRB,0.2,19,cardiac,synthesis and degradation of ketone bodies
149,BMD_A,TMEM33,-0.2,90,smooth,fatty acid degradation
150,BMD_A,SMC1A,NA,82,smooth,synthesis and degradation of ketone bodies
151,DMD_A,NF1,0.3,17,smooth,focal adhesion
152,DMD_A,UEVLD,-0.1,68,smooth,Wnt signalling
153,DMD_A,CDC37L1,-0.3,63,smooth,cancer pathways
154,DMD_A,HOXD10,-0.2,66,smooth,Wnt signalling
155,DMD_A,NNT,-0.4,39,cardiac,synthesis and degradation of ketone bodies
156,DMD_A,HUWE1,0.1,64,skeletal,apoptosis
157,DMD_A,GJA5,-0.1,81,cardiac,MAPK
158,DMD_A,SPCS3,0.6,97,skeletal,cancer pathways
159,DMD_A,DOT1L,-0.2,42,smooth,focal adhesion
160,DMD_A,ATP6V0E1,0.4,5,smooth,Wnt signalling
161,DMD_A,XAF1,0.1,81,cardiac,apoptosis
162,DMD_A,MAFG,-0.5,65,skeletal,citrate cycle
163,DMD_A,AAK1,0.1,76,cardiac,focal adhesion
164,DMD_A,TM2D3,0.1,59,skeletal,fatty acid degradation
165,DMD_A,SSR3,-0.1,58,cardiac,fatty acid degradation
166,DMD_A,ZNF281,-0.2,50,cardiac,cancer pathways
167,DMD_A,JAM2,1,32,skeletal,pyruvate metabolism
168,DMD_A,CDC23,0.5,2,cardiac,citrate cycle
169,DMD_A,PLN,-0.6,0,skeletal,propanoate metabolism
170,DMD_A,PGP,-0.2,31,smooth,focal adhesion
171,DMD_A,HYI,-0.1,13,skeletal,MAPK
172,DMD_A,IMPACT,0.3,55,smooth,propanoate metabolism
173,DMD_A,C2orf49,-0.2,41,skeletal,focal adhesion
174,DMD_A,HDAC11,-0.3,91,smooth,citrate cycle
175,DMD_A,CCN4,-0.4,9,skeletal,Wnt signalling
176,DMD_A,MKLN1,-0.1,51,smooth,Wnt signalling
177,DMD_A,GPRC5B,NA,47,skeletal,fatty acid degradation
178,DMD_A,RPS6KB1,-0.1,15,skeletal,Wnt signalling
179,DMD_A,PSMA3,-0.1,72,skeletal,citrate cycle
180,DMD_A,JARID2,0.1,26,cardiac,fatty acid degradation
181,DMD_A,ODF2,-0.3,39,smooth,citrate cycle
182,DMD_A,MON2,0.3,80,skeletal,citrate cycle
183,DMD_A,PDLIM2,-0.8,2,smooth,synthesis and degradation of ketone bodies
184,DMD_A,WAC,0.5,67,smooth,focal adhesion
185,DMD_A,FLCN,0.1,63,smooth,focal adhesion
186,DMD_A,ATF6,NA,3,skeletal,Wnt signalling
187,DMD_A,TRAFD1,0.2,78,skeletal,focal adhesion
188,DMD_A,BICD1,-0.1,61,smooth,pyruvate metabolism
189,DMD_A,ANP32A,0.3,32,cardiac,apoptosis
190,DMD_A,KDSR,0.2,66,smooth,fatty acid degradation
191,DMD_A,FBXO9,0.3,77,cardiac,pyruvate metabolism
192,DMD_A,UBQLN2,0.1,39,smooth,focal adhesion
193,DMD_A,ZFX,-0.4,37,smooth,MAPK
194,DMD_A,CPLX2,-0.2,30,smooth,apoptosis
195,DMD_A,CLPX,-0.3,63,smooth,Wnt signalling
196,DMD_A,SGCB,-0.2,46,skeletal,cancer pathways
197,DMD_A,SEMA5A,-0.3,64,skeletal,propanoate metabolism
198,DMD_A,PTPRB,0.3,39,cardiac,apoptosis
199,DMD_A,TMEM33,0.1,73,skeletal,cancer pathways
200,DMD_A,SMC1A,0.5,52,skeletal,fatty acid degradation
201,EDMD.AD_A,NF1,0.7,18,skeletal,apoptosis
202,EDMD.AD_A,UEVLD,-0.2,81,cardiac,MAPK
203,EDMD.AD_A,CDC37L1,0.6,3,smooth,propanoate metabolism
204,EDMD.AD_A,HOXD10,-0.4,52,cardiac,Wnt signalling
205,EDMD.AD_A,NNT,-0.3,60,smooth,fatty acid degradation
206,EDMD.AD_A,HUWE1,0.4,32,skeletal,fatty acid degradation
207,EDMD.AD_A,GJA5,NA,80,skeletal,fatty acid degradation
208,EDMD.AD_A,SPCS3,0.5,74,skeletal,Wnt signalling
209,EDMD.AD_A,DOT1L,-0.2,28,cardiac,fatty acid degradation
210,EDMD.AD_A,ATP6V0E1,0.5,52,skeletal,cancer pathways
211,EDMD.AD_A,XAF1,-0.2,76,smooth,focal adhesion
212,EDMD.AD_A,MAFG,-0.3,29,cardiac,fatty acid degradation
213,EDMD.AD_A,AAK1,0.2,1,skeletal,apoptosis
214,EDMD.AD_A,TM2D3,0.6,79,smooth,apoptosis
215,EDMD.AD_A,SSR3,-0.4,55,smooth,focal adhesion
216,EDMD.AD_A,ZNF281,-0.3,59,cardiac,cancer pathways
217,EDMD.AD_A,JAM2,0.5,27,smooth,MAPK
218,EDMD.AD_A,CDC23,0.6,91,smooth,MAPK
219,EDMD.AD_A,PLN,-0.5,32,cardiac,propanoate metabolism
220,EDMD.AD_A,PGP,-0.2,99,cardiac,Wnt signalling
221,EDMD.AD_A,HYI,-0.1,42,cardiac,apoptosis
222,EDMD.AD_A,IMPACT,0.3,22,smooth,citrate cycle
223,EDMD.AD_A,C2orf49,-0.1,98,cardiac,MAPK
224,EDMD.AD_A,HDAC11,-0.3,22,cardiac,MAPK
225,EDMD.AD_A,CCN4,-0.4,41,cardiac,propanoate metabolism
226,EDMD.AD_A,MKLN1,0.2,69,skeletal,MAPK
227,EDMD.AD_A,GPRC5B,0.2,34,smooth,fatty acid degradation
228,EDMD.AD_A,RPS6KB1,NA,97,skeletal,pyruvate metabolism
229,EDMD.AD_A,PSMA3,0.3,64,smooth,Wnt signalling
230,EDMD.AD_A,JARID2,0.1,57,cardiac,synthesis and degradation of ketone bodies
231,EDMD.AD_A,ODF2,-0.2,79,skeletal,MAPK
232,EDMD.AD_A,MON2,0.4,55,cardiac,propanoate metabolism
233,EDMD.AD_A,PDLIM2,-0.6,75,smooth,fatty acid degradation
234,EDMD.AD_A,WAC,1,53,smooth,citrate cycle
235,EDMD.AD_A,FLCN,0.1,81,cardiac,pyruvate metabolism
236,EDMD.AD_A,ATF6,NA,44,cardiac,pyruvate metabolism
237,EDMD.AD_A,TRAFD1,NA,96,smooth,Wnt signalling
238,EDMD.AD_A,BICD1,-0.2,85,cardiac,Wnt signalling
239,EDMD.AD_A,ANP32A,0.5,91,smooth,cancer pathways
240,EDMD.AD_A,KDSR,0.2,95,cardiac,synthesis and degradation of ketone bodies
241,EDMD.AD_A,FBXO9,-0.1,26,smooth,citrate cycle
242,EDMD.AD_A,UBQLN2,0.7,77,smooth,fatty acid degradation
243,EDMD.AD_A,ZFX,-0.4,23,skeletal,focal adhesion
244,EDMD.AD_A,CPLX2,-0.3,98,smooth,pyruvate metabolism
245,EDMD.AD_A,CLPX,0.3,93,cardiac,citrate cycle
246,EDMD.AD_A,SGCB,-0.3,37,smooth,fatty acid degradation
247,EDMD.AD_A,SEMA5A,-0.1,25,skeletal,pyruvate metabolism
248,EDMD.AD_A,PTPRB,-0.3,64,smooth,Wnt signalling
249,EDMD.AD_A,TMEM33,0.2,40,skeletal,Wnt signalling
250,EDMD.AD_A,SMC1A,0.9,65,smooth,Wnt signalling
251,EDMD.XR_A,NF1,0.2,62,cardiac,apoptosis
252,EDMD.XR_A,UEVLD,NA,62,cardiac,focal adhesion
253,EDMD.XR_A,CDC37L1,0.6,59,smooth,propanoate metabolism
254,EDMD.XR_A,HOXD10,NA,72,cardiac,pyruvate metabolism
255,EDMD.XR_A,NNT,-0.1,59,cardiac,citrate cycle
256,EDMD.XR_A,HUWE1,0.3,49,cardiac,Wnt signalling
257,EDMD.XR_A,GJA5,NA,88,cardiac,MAPK
258,EDMD.XR_A,SPCS3,0.4,49,smooth,synthesis and degradation of ketone bodies
259,EDMD.XR_A,DOT1L,NA,11,cardiac,MAPK
260,EDMD.XR_A,ATP6V0E1,0.4,36,skeletal,propanoate metabolism
261,EDMD.XR_A,XAF1,NA,8,skeletal,synthesis and degradation of ketone bodies
262,EDMD.XR_A,MAFG,-0.3,52,cardiac,Wnt signalling
263,EDMD.XR_A,AAK1,NA,32,smooth,fatty acid degradation
264,EDMD.XR_A,TM2D3,0.4,67,smooth,focal adhesion
265,EDMD.XR_A,SSR3,NA,15,cardiac,MAPK
266,EDMD.XR_A,ZNF281,NA,45,skeletal,focal adhesion
267,EDMD.XR_A,JAM2,NA,59,skeletal,apoptosis
268,EDMD.XR_A,CDC23,0.3,53,cardiac,synthesis and degradation of ketone bodies
269,EDMD.XR_A,PLN,-0.3,9,skeletal,cancer pathways
270,EDMD.XR_A,PGP,-0.1,33,cardiac,synthesis and degradation of ketone bodies
271,EDMD.XR_A,HYI,0.1,100,skeletal,fatty acid degradation
272,EDMD.XR_A,IMPACT,NA,22,smooth,Wnt signalling
273,EDMD.XR_A,C2orf49,NA,17,skeletal,citrate cycle
274,EDMD.XR_A,HDAC11,NA,38,smooth,focal adhesion
275,EDMD.XR_A,CCN4,NA,44,cardiac,citrate cycle
276,EDMD.XR_A,MKLN1,NA,69,cardiac,Wnt signalling
277,EDMD.XR_A,GPRC5B,0.1,58,skeletal,MAPK
278,EDMD.XR_A,RPS6KB1,0.1,93,skeletal,citrate cycle
279,EDMD.XR_A,PSMA3,0.1,52,skeletal,pyruvate metabolism
280,EDMD.XR_A,JARID2,NA,35,smooth,focal adhesion
281,EDMD.XR_A,ODF2,-0.2,68,cardiac,propanoate metabolism
282,EDMD.XR_A,MON2,NA,5,smooth,MAPK
283,EDMD.XR_A,PDLIM2,-0.6,58,cardiac,pyruvate metabolism
284,EDMD.XR_A,WAC,0.5,57,smooth,cancer pathways
285,EDMD.XR_A,FLCN,NA,5,cardiac,citrate cycle
286,EDMD.XR_A,ATF6,NA,90,cardiac,propanoate metabolism
287,EDMD.XR_A,TRAFD1,NA,16,smooth,pyruvate metabolism
288,EDMD.XR_A,BICD1,NA,8,smooth,fatty acid degradation
289,EDMD.XR_A,ANP32A,0.5,91,cardiac,cancer pathways
290,EDMD.XR_A,KDSR,0.2,37,cardiac,cancer pathways
291,EDMD.XR_A,FBXO9,0.2,92,skeletal,apoptosis
292,EDMD.XR_A,UBQLN2,0.3,75,skeletal,synthesis and degradation of ketone bodies
293,EDMD.XR_A,ZFX,NA,22,cardiac,fatty acid degradation
294,EDMD.XR_A,CPLX2,NA,68,skeletal,MAPK
295,EDMD.XR_A,CLPX,NA,69,skeletal,pyruvate metabolism
296,EDMD.XR_A,SGCB,-0.2,60,cardiac,cancer pathways
297,EDMD.XR_A,SEMA5A,NA,46,cardiac,Wnt signalling
298,EDMD.XR_A,PTPRB,-0.4,56,smooth,synthesis and degradation of ketone bodies
299,EDMD.XR_A,TMEM33,0.3,31,smooth,apoptosis
300,EDMD.XR_A,SMC1A,0.1,80,smooth,citrate cycle
301,FSHD_A,NF1,0.1,67,skeletal,Wnt signalling
302,FSHD_A,UEVLD,0.1,77,cardiac,MAPK
303,FSHD_A,CDC37L1,-0.1,89,skeletal,synthesis and degradation of ketone bodies
304,FSHD_A,HOXD10,-0.2,85,cardiac,focal adhesion
305,FSHD_A,NNT,NA,74,smooth,synthesis and degradation of ketone bodies
306,FSHD_A,HUWE1,0.3,37,cardiac,fatty acid degradation
307,FSHD_A,GJA5,-0.1,13,cardiac,cancer pathways
308,FSHD_A,SPCS3,0.4,57,smooth,fatty acid degradation
309,FSHD_A,DOT1L,NA,22,smooth,focal adhesion
310,FSHD_A,ATP6V0E1,0.2,75,skeletal,pyruvate metabolism
311,FSHD_A,XAF1,0.1,78,cardiac,cancer pathways
312,FSHD_A,MAFG,0.3,27,skeletal,citrate cycle
313,FSHD_A,AAK1,0.3,59,cardiac,focal adhesion
314,FSHD_A,TM2D3,0.6,46,skeletal,apoptosis
315,FSHD_A,SSR3,-0.1,82,cardiac,Wnt signalling
316,FSHD_A,ZNF281,0.3,79,smooth,focal adhesion
317,FSHD_A,JAM2,0.2,48,skeletal,Wnt signalling
318,FSHD_A,CDC23,0.3,56,smooth,citrate cycle
319,FSHD_A,PLN,-0.1,2,cardiac,cancer pathways
320,FSHD_A,PGP,-0.1,98,cardiac,fatty acid degradation
321,FSHD_A,HYI,-0.1,56,skeletal,fatty acid degradation
322,FSHD_A,IMPACT,0.2,49,smooth,apoptosis
323,FSHD_A,C2orf49,-0.1,54,cardiac,synthesis and degradation of ketone bodies
324,FSHD_A,HDAC11,-0.2,56,skeletal,fatty acid degradation
325,FSHD_A,CCN4,-0.2,61,cardiac,pyruvate metabolism
326,FSHD_A,MKLN1,NA,34,cardiac,focal adhesion
327,FSHD_A,GPRC5B,0.4,84,skeletal,pyruvate metabolism
328,FSHD_A,RPS6KB1,0.4,40,smooth,citrate cycle
329,FSHD_A,PSMA3,0.3,68,skeletal,pyruvate metabolism
330,FSHD_A,JARID2,-0.1,77,smooth,fatty acid degradation
331,FSHD_A,ODF2,-0.1,13,smooth,citrate cycle
332,FSHD_A,MON2,0.2,63,skeletal,apoptosis
333,FSHD_A,PDLIM2,-0.1,31,smooth,pyruvate metabolism
334,FSHD_A,WAC,0.2,18,cardiac,cancer pathways
335,FSHD_A,FLCN,0.1,67,skeletal,focal adhesion
336,FSHD_A,ATF6,NA,87,smooth,apoptosis
337,FSHD_A,TRAFD1,NA,21,smooth,fatty acid degradation
338,FSHD_A,BICD1,-0.2,2,skeletal,MAPK
339,FSHD_A,ANP32A,0.3,47,cardiac,fatty acid degradation
340,FSHD_A,KDSR,0.4,85,cardiac,propanoate metabolism
341,FSHD_A,FBXO9,0.1,73,skeletal,MAPK
342,FSHD_A,UBQLN2,0.9,68,skeletal,citrate cycle
343,FSHD_A,ZFX,-0.2,48,skeletal,propanoate metabolism
344,FSHD_A,CPLX2,-0.3,10,skeletal,propanoate metabolism
345,FSHD_A,CLPX,0.3,71,smooth,Wnt signalling
346,FSHD_A,SGCB,0.3,35,smooth,propanoate metabolism
347,FSHD_A,SEMA5A,-0.3,4,cardiac,MAPK
348,FSHD_A,PTPRB,0.1,90,skeletal,pyruvate metabolism
349,FSHD_A,TMEM33,0.3,74,smooth,focal adhesion
350,FSHD_A,SMC1A,0.7,48,skeletal,pyruvate metabolism
351,HSP_A,NF1,-0.6,9,cardiac,synthesis and degradation of ketone bodies
352,HSP_A,UEVLD,-0.3,5,skeletal,Wnt signalling
353,HSP_A,CDC37L1,-0.9,55,smooth,synthesis and degradation of ketone bodies
354,HSP_A,HOXD10,0.2,85,skeletal,cancer pathways
355,HSP_A,NNT,-1.8,54,smooth,cancer pathways
356,HSP_A,HUWE1,0.1,3,smooth,cancer pathways
357,HSP_A,GJA5,0.4,47,skeletal,apoptosis
358,HSP_A,SPCS3,-0.5,82,smooth,pyruvate metabolism
359,HSP_A,DOT1L,0.2,70,smooth,fatty acid degradation
360,HSP_A,ATP6V0E1,-0.2,82,cardiac,citrate cycle
361,HSP_A,XAF1,-0.1,69,skeletal,propanoate metabolism
362,HSP_A,MAFG,0.3,13,skeletal,propanoate metabolism
363,HSP_A,AAK1,-0.1,39,cardiac,citrate cycle
364,HSP_A,TM2D3,-0.3,62,smooth,focal adhesion
365,HSP_A,SSR3,-0.4,18,smooth,focal adhesion
366,HSP_A,ZNF281,-0.3,47,skeletal,synthesis and degradation of ketone bodies
367,HSP_A,JAM2,NA,93,smooth,citrate cycle
368,HSP_A,CDC23,NA,76,skeletal,citrate cycle
369,HSP_A,PLN,-0.8,5,cardiac,Wnt signalling
370,HSP_A,PGP,0.3,57,skeletal,pyruvate metabolism
371,HSP_A,HYI,0.5,42,smooth,propanoate metabolism
372,HSP_A,IMPACT,NA,12,skeletal,pyruvate metabolism
373,HSP_A,C2orf49,-0.3,36,smooth,MAPK
374,HSP_A,HDAC11,NA,14,cardiac,cancer pathways
375,HSP_A,CCN4,NA,4,smooth,Wnt signalling
376,HSP_A,MKLN1,NA,46,cardiac,propanoate metabolism
377,HSP_A,GPRC5B,0.3,74,cardiac,MAPK
378,HSP_A,RPS6KB1,-0.3,94,skeletal,apoptosis
379,HSP_A,PSMA3,-1,3,cardiac,Wnt signalling
380,HSP_A,JARID2,NA,10,skeletal,citrate cycle
381,HSP_A,ODF2,0.3,79,cardiac,Wnt signalling
382,HSP_A,MON2,-0.3,37,cardiac,fatty acid degradation
383,HSP_A,PDLIM2,0.6,76,skeletal,pyruvate metabolism
384,HSP_A,WAC,-0.4,82,cardiac,propanoate metabolism
385,HSP_A,FLCN,NA,83,smooth,fatty acid degradation
386,HSP_A,ATF6,NA,57,smooth,fatty acid degradation
387,HSP_A,TRAFD1,NA,92,cardiac,synthesis and degradation of ketone bodies
388,HSP_A,BICD1,NA,60,smooth,apoptosis
389,HSP_A,ANP32A,-0.3,25,smooth,pyruvate metabolism
390,HSP_A,KDSR,-0.4,62,skeletal,synthesis and degradation of ketone bodies
391,HSP_A,FBXO9,-0.5,91,cardiac,focal adhesion
392,HSP_A,UBQLN2,-0.6,56,cardiac,citrate cycle
393,HSP_A,ZFX,-0.3,6,smooth,apoptosis
394,HSP_A,CPLX2,0.2,22,skeletal,apoptosis
395,HSP_A,CLPX,-0.4,42,skeletal,apoptosis
396,HSP_A,SGCB,-0.1,51,skeletal,fatty acid degradation
397,HSP_A,SEMA5A,NA,54,skeletal,MAPK
398,HSP_A,PTPRB,-0.5,60,smooth,synthesis and degradation of ketone bodies
399,HSP_A,TMEM33,-0.3,32,skeletal,propanoate metabolism
400,HSP_A,SMC1A,-0.4,23,smooth,pyruvate metabolism
401,JDM_A,NF1,0.3,97,skeletal,citrate cycle
402,JDM_A,UEVLD,0.2,13,skeletal,propanoate metabolism
403,JDM_A,CDC37L1,0.6,17,smooth,propanoate metabolism
404,JDM_A,HOXD10,-0.3,60,cardiac,pyruvate metabolism
405,JDM_A,NNT,-1,97,skeletal,Wnt signalling
406,JDM_A,HUWE1,0.2,25,cardiac,fatty acid degradation
407,JDM_A,GJA5,-0.2,98,cardiac,pyruvate metabolism
408,JDM_A,SPCS3,0.7,64,skeletal,Wnt signalling
409,JDM_A,DOT1L,-0.4,80,smooth,Wnt signalling
410,JDM_A,ATP6V0E1,0.5,24,cardiac,citrate cycle
411,JDM_A,XAF1,3.1,65,cardiac,propanoate metabolism
412,JDM_A,MAFG,0.2,12,cardiac,focal adhesion
413,JDM_A,AAK1,0.6,14,skeletal,MAPK
414,JDM_A,TM2D3,0.8,51,skeletal,cancer pathways
415,JDM_A,SSR3,-0.1,84,skeletal,Wnt signalling
416,JDM_A,ZNF281,0.3,79,smooth,fatty acid degradation
417,JDM_A,JAM2,0.4,11,cardiac,synthesis and degradation of ketone bodies
418,JDM_A,CDC23,1,47,cardiac,cancer pathways
419,JDM_A,PLN,-0.5,34,skeletal,MAPK
420,JDM_A,PGP,-0.3,70,smooth,MAPK
421,JDM_A,HYI,-0.3,29,cardiac,cancer pathways
422,JDM_A,IMPACT,0.3,51,skeletal,propanoate metabolism
423,JDM_A,C2orf49,NA,5,smooth,citrate cycle
424,JDM_A,HDAC11,-0.4,16,skeletal,cancer pathways
425,JDM_A,CCN4,-0.5,52,cardiac,Wnt signalling
426,JDM_A,MKLN1,0.3,11,smooth,MAPK
427,JDM_A,GPRC5B,NA,5,cardiac,pyruvate metabolism
428,JDM_A,RPS6KB1,0.6,29,skeletal,synthesis and degradation of ketone bodies
429,JDM_A,PSMA3,0.6,20,cardiac,focal adhesion
430,JDM_A,JARID2,0.1,92,smooth,synthesis and degradation of ketone bodies
431,JDM_A,ODF2,-0.4,87,cardiac,MAPK
432,JDM_A,MON2,0.6,45,skeletal,propanoate metabolism
433,JDM_A,PDLIM2,-0.4,39,cardiac,Wnt signalling
434,JDM_A,WAC,0.9,26,skeletal,MAPK
435,JDM_A,FLCN,0.4,63,cardiac,pyruvate metabolism
436,JDM_A,ATF6,0.1,5,skeletal,pyruvate metabolism
437,JDM_A,TRAFD1,0.6,98,smooth,synthesis and degradation of ketone bodies
438,JDM_A,BICD1,-0.3,59,smooth,fatty acid degradation
439,JDM_A,ANP32A,0.5,14,cardiac,synthesis and degradation of ketone bodies
440,JDM_A,KDSR,0.6,9,smooth,pyruvate metabolism
441,JDM_A,FBXO9,0.3,91,smooth,cancer pathways
442,JDM_A,UBQLN2,0.9,12,smooth,focal adhesion
443,JDM_A,ZFX,-0.2,51,cardiac,synthesis and degradation of ketone bodies
444,JDM_A,CPLX2,-0.4,99,skeletal,MAPK
445,JDM_A,CLPX,0.3,86,smooth,propanoate metabolism
446,JDM_A,SGCB,0.2,65,cardiac,propanoate metabolism
447,JDM_A,SEMA5A,-0.4,81,smooth,cancer pathways
448,JDM_A,PTPRB,0.1,27,skeletal,propanoate metabolism
449,JDM_A,TMEM33,0.5,30,cardiac,propanoate metabolism
450,JDM_A,SMC1A,1.6,92,cardiac,citrate cycle
451,LGMD2A_A,NF1,0.1,65,cardiac,propanoate metabolism
452,LGMD2A_A,UEVLD,-0.2,48,smooth,MAPK
453,LGMD2A_A,CDC37L1,-0.4,6,cardiac,citrate cycle
454,LGMD2A_A,HOXD10,-0.1,6,smooth,pyruvate metabolism
455,LGMD2A_A,NNT,-0.8,8,smooth,apoptosis
456,LGMD2A_A,HUWE1,0.1,71,smooth,MAPK
457,LGMD2A_A,GJA5,NA,37,cardiac,apoptosis
458,LGMD2A_A,SPCS3,0.2,95,skeletal,Wnt signalling
459,LGMD2A_A,DOT1L,-0.1,14,skeletal,focal adhesion
460,LGMD2A_A,ATP6V0E1,0.2,79,smooth,synthesis and degradation of ketone bodies
461,LGMD2A_A,XAF1,NA,82,cardiac,synthesis and degradation of ketone bodies
462,LGMD2A_A,MAFG,-0.1,91,smooth,fatty acid degradation
463,LGMD2A_A,AAK1,NA,84,skeletal,fatty acid degradation
464,LGMD2A_A,TM2D3,-0.1,20,skeletal,apoptosis
465,LGMD2A_A,SSR3,-0.3,44,smooth,citrate cycle
466,LGMD2A_A,ZNF281,-0.2,95,cardiac,cancer pathways
467,LGMD2A_A,JAM2,0.4,93,skeletal,MAPK
468,LGMD2A_A,CDC23,0.1,29,skeletal,propanoate metabolism
469,LGMD2A_A,PLN,-0.9,16,skeletal,citrate cycle
470,LGMD2A_A,PGP,0.1,10,skeletal,propanoate metabolism
471,LGMD2A_A,HYI,0.2,76,skeletal,propanoate metabolism
472,LGMD2A_A,IMPACT,NA,37,smooth,pyruvate metabolism
473,LGMD2A_A,C2orf49,-0.3,54,cardiac,propanoate metabolism
474,LGMD2A_A,HDAC11,NA,100,cardiac,cancer pathways
475,LGMD2A_A,CCN4,-0.2,80,skeletal,pyruvate metabolism
476,LGMD2A_A,MKLN1,-0.2,7,smooth,fatty acid degradation
477,LGMD2A_A,GPRC5B,NA,28,smooth,citrate cycle
478,LGMD2A_A,RPS6KB1,-0.2,28,skeletal,cancer pathways
479,LGMD2A_A,PSMA3,-0.2,92,smooth,focal adhesion
480,LGMD2A_A,JARID2,0.1,64,cardiac,synthesis and degradation of ketone bodies
481,LGMD2A_A,ODF2,NA,47,cardiac,fatty acid degradation
482,LGMD2A_A,MON2,-0.2,95,smooth,MAPK
483,LGMD2A_A,PDLIM2,-0.7,56,cardiac,cancer pathways
484,LGMD2A_A,WAC,0.1,82,smooth,cancer pathways
485,LGMD2A_A,FLCN,-0.1,39,cardiac,fatty acid degradation
486,LGMD2A_A,ATF6,NA,0,cardiac,cancer pathways
487,LGMD2A_A,TRAFD1,NA,74,cardiac,citrate cycle
488,LGMD2A_A,BICD1,NA,48,cardiac,Wnt signalling
489,LGMD2A_A,ANP32A,0.1,30,skeletal,focal adhesion
490,LGMD2A_A,KDSR,-0.1,6,skeletal,MAPK
491,LGMD2A_A,FBXO9,NA,89,cardiac,pyruvate metabolism
492,LGMD2A_A,UBQLN2,-0.3,85,cardiac,apoptosis
493,LGMD2A_A,ZFX,-0.3,23,smooth,apoptosis
494,LGMD2A_A,CPLX2,NA,74,skeletal,MAPK
495,LGMD2A_A,CLPX,-0.3,78,cardiac,citrate cycle
496,LGMD2A_A,SGCB,-0.1,89,cardiac,pyruvate metabolism
497,LGMD2A_A,SEMA5A,NA,91,cardiac,apoptosis
498,LGMD2A_A,PTPRB,-0.3,49,cardiac,pyruvate metabolism
499,LGMD2A_A,TMEM33,-0.2,88,smooth,propanoate metabolism
500,LGMD2A_A,SMC1A,0.1,17,cardiac,apoptosis
501,LGMD2B_A,NF1,0.1,11,skeletal,MAPK
502,LGMD2B_A,UEVLD,-0.2,39,skeletal,citrate cycle
503,LGMD2B_A,CDC37L1,-0.2,89,skeletal,Wnt signalling
504,LGMD2B_A,HOXD10,0.1,6,skeletal,MAPK
505,LGMD2B_A,NNT,-0.8,72,skeletal,focal adhesion
506,LGMD2B_A,HUWE1,0.1,87,cardiac,pyruvate metabolism
507,LGMD2B_A,GJA5,NA,72,smooth,citrate cycle
508,LGMD2B_A,SPCS3,0.3,56,skeletal,citrate cycle
509,LGMD2B_A,DOT1L,NA,25,cardiac,apoptosis
510,LGMD2B_A,ATP6V0E1,0.1,54,cardiac,Wnt signalling
511,LGMD2B_A,XAF1,NA,9,smooth,focal adhesion
512,LGMD2B_A,MAFG,-0.2,9,cardiac,apoptosis
513,LGMD2B_A,AAK1,0.2,18,smooth,MAPK
514,LGMD2B_A,TM2D3,-0.1,38,cardiac,Wnt signalling
515,LGMD2B_A,SSR3,-0.3,49,smooth,apoptosis
516,LGMD2B_A,ZNF281,-0.4,79,skeletal,MAPK
517,LGMD2B_A,JAM2,0.1,42,cardiac,apoptosis
518,LGMD2B_A,CDC23,0.1,20,skeletal,fatty acid degradation
519,LGMD2B_A,PLN,-0.9,33,cardiac,propanoate metabolism
520,LGMD2B_A,PGP,0.1,92,smooth,Wnt signalling
521,LGMD2B_A,HYI,0.1,39,smooth,synthesis and degradation of ketone bodies
522,LGMD2B_A,IMPACT,-0.1,54,cardiac,synthesis and degradation of ketone bodies
523,LGMD2B_A,C2orf49,-0.2,91,skeletal,apoptosis
524,LGMD2B_A,HDAC11,NA,64,cardiac,fatty acid degradation
525,LGMD2B_A,CCN4,-0.2,28,smooth,focal adhesion
526,LGMD2B_A,MKLN1,-0.1,83,skeletal,citrate cycle
527,LGMD2B_A,GPRC5B,-0.3,44,smooth,cancer pathways
528,LGMD2B_A,RPS6KB1,-0.2,21,skeletal,fatty acid degradation
529,LGMD2B_A,PSMA3,-0.4,39,skeletal,focal adhesion
530,LGMD2B_A,JARID2,0.1,49,cardiac,focal adhesion
531,LGMD2B_A,ODF2,-0.1,55,smooth,cancer pathways
532,LGMD2B_A,MON2,-0.1,0,smooth,propanoate metabolism
533,LGMD2B_A,PDLIM2,-0.8,60,smooth,apoptosis
534,LGMD2B_A,WAC,-0.2,88,skeletal,MAPK
535,LGMD2B_A,FLCN,NA,35,smooth,synthesis and degradation of ketone bodies
536,LGMD2B_A,ATF6,-0.1,78,smooth,cancer pathways
537,LGMD2B_A,TRAFD1,0.2,75,smooth,Wnt signalling
538,LGMD2B_A,BICD1,NA,83,smooth,apoptosis
539,LGMD2B_A,ANP32A,-0.2,76,skeletal,focal adhesion
540,LGMD2B_A,KDSR,-0.4,73,smooth,propanoate metabolism
541,LGMD2B_A,FBXO9,NA,5,smooth,fatty acid degradation
542,LGMD2B_A,UBQLN2,-0.2,62,cardiac,focal adhesion
543,LGMD2B_A,ZFX,-0.4,83,skeletal,focal adhesion
544,LGMD2B_A,CPLX2,0.2,35,cardiac,synthesis and degradation of ketone bodies
545,LGMD2B_A,CLPX,-0.3,62,skeletal,MAPK
546,LGMD2B_A,SGCB,-0.1,85,cardiac,propanoate metabolism
547,LGMD2B_A,SEMA5A,-0.1,16,cardiac,MAPK
548,LGMD2B_A,PTPRB,-0.2,32,cardiac,cancer pathways
549,LGMD2B_A,TMEM33,-0.3,82,smooth,apoptosis
550,LGMD2B_A,SMC1A,NA,6,skeletal,synthesis and degradation of ketone bodies
551,LGMD2I_A,NF1,0.1,22,smooth,pyruvate metabolism
552,LGMD2I_A,UEVLD,-0.2,18,cardiac,apoptosis
553,LGMD2I_A,CDC37L1,0.2,13,skeletal,pyruvate metabolism
554,LGMD2I_A,HOXD10,0.1,73,cardiac,MAPK
555,LGMD2I_A,NNT,-0.3,45,smooth,apoptosis
556,LGMD2I_A,HUWE1,0.1,72,smooth,MAPK
557,LGMD2I_A,GJA5,NA,18,smooth,focal adhesion
558,LGMD2I_A,SPCS3,0.3,5,skeletal,Wnt signalling
559,LGMD2I_A,DOT1L,0.2,66,skeletal,MAPK
560,LGMD2I_A,ATP6V0E1,0.2,17,skeletal,fatty acid degradation
561,LGMD2I_A,XAF1,0.1,96,smooth,synthesis and degradation of ketone bodies
562,LGMD2I_A,MAFG,-0.3,89,skeletal,focal adhesion
563,LGMD2I_A,AAK1,0.1,53,skeletal,pyruvate metabolism
564,LGMD2I_A,TM2D3,NA,28,skeletal,citrate cycle
565,LGMD2I_A,SSR3,-0.1,57,smooth,pyruvate metabolism
566,LGMD2I_A,ZNF281,-0.2,83,cardiac,focal adhesion
567,LGMD2I_A,JAM2,0.1,10,skeletal,fatty acid degradation
568,LGMD2I_A,CDC23,0.1,98,cardiac,Wnt signalling
569,LGMD2I_A,PLN,-0.1,89,cardiac,fatty acid degradation
570,LGMD2I_A,PGP,0.2,88,skeletal,cancer pathways
571,LGMD2I_A,HYI,0.2,85,smooth,citrate cycle
572,LGMD2I_A,IMPACT,-0.1,14,skeletal,fatty acid degradation
573,LGMD2I_A,C2orf49,-0.3,3,skeletal,apoptosis
574,LGMD2I_A,HDAC11,NA,89,skeletal,focal adhesion
575,LGMD2I_A,CCN4,-0.2,100,skeletal,propanoate metabolism
576,LGMD2I_A,MKLN1,-0.2,87,cardiac,apoptosis
577,LGMD2I_A,GPRC5B,NA,30,smooth,MAPK
578,LGMD2I_A,RPS6KB1,-0.2,15,skeletal,pyruvate metabolism
579,LGMD2I_A,PSMA3,0.2,78,cardiac,cancer pathways
580,LGMD2I_A,JARID2,-0.1,0,cardiac,Wnt signalling
581,LGMD2I_A,ODF2,-0.1,84,cardiac,Wnt signalling
582,LGMD2I_A,MON2,-0.3,91,skeletal,MAPK
583,LGMD2I_A,PDLIM2,-0.4,43,smooth,focal adhesion
584,LGMD2I_A,WAC,-0.1,8,smooth,apoptosis
585,LGMD2I_A,FLCN,NA,69,cardiac,pyruvate metabolism
586,LGMD2I_A,ATF6,NA,93,cardiac,propanoate metabolism
587,LGMD2I_A,TRAFD1,0.3,15,skeletal,citrate cycle
588,LGMD2I_A,BICD1,0.1,7,skeletal,MAPK
589,LGMD2I_A,ANP32A,NA,76,skeletal,synthesis and degradation of ketone bodies
590,LGMD2I_A,KDSR,-0.4,70,smooth,pyruvate metabolism
591,LGMD2I_A,FBXO9,NA,95,cardiac,Wnt signalling
592,LGMD2I_A,UBQLN2,-0.2,37,skeletal,propanoate metabolism
593,LGMD2I_A,ZFX,-0.3,67,cardiac,focal adhesion
594,LGMD2I_A,CPLX2,0.1,17,skeletal,focal adhesion
595,LGMD2I_A,CLPX,-0.1,49,cardiac,apoptosis
596,LGMD2I_A,SGCB,-0.2,55,skeletal,fatty acid degradation
597,LGMD2I_A,SEMA5A,NA,41,cardiac,MAPK
598,LGMD2I_A,PTPRB,0.1,92,smooth,propanoate metabolism
599,LGMD2I_A,TMEM33,-0.3,15,cardiac,fatty acid degradation
600,LGMD2I_A,SMC1A,0.1,44,smooth,synthesis and degradation of ketone bodies
601,ALS_B,NF1,0.1,18,smooth,apoptosis
602,ALS_B,UEVLD,0.1,22,cardiac,focal adhesion
603,ALS_B,CDC37L1,0.5,91,skeletal,citrate cycle
604,ALS_B,HOXD10,-0.1,28,skeletal,fatty acid degradation
605,ALS_B,NNT,NA,41,smooth,citrate cycle
606,ALS_B,HUWE1,0.1,81,smooth,Wnt signalling
607,ALS_B,GJA5,-0.3,39,skeletal,focal adhesion
608,ALS_B,SPCS3,-0.1,96,skeletal,synthesis and degradation of ketone bodies
609,ALS_B,DOT1L,0.2,39,smooth,synthesis and degradation of ketone bodies
610,ALS_B,ATP6V0E1,0.4,73,skeletal,citrate cycle
611,ALS_B,XAF1,0.1,95,smooth,fatty acid degradation
612,ALS_B,MAFG,-0.3,24,smooth,cancer pathways
613,ALS_B,AAK1,0.4,13,smooth,focal adhesion
614,ALS_B,TM2D3,0.3,76,cardiac,cancer pathways
615,ALS_B,SSR3,0.3,57,cardiac,apoptosis
616,ALS_B,ZNF281,0.4,82,smooth,apoptosis
617,ALS_B,JAM2,0.2,94,smooth,synthesis and degradation of ketone bodies
618,ALS_B,CDC23,0.1,0,skeletal,citrate cycle
619,ALS_B,PLN,-0.5,54,cardiac,MAPK
620,ALS_B,PGP,-0.1,56,smooth,propanoate metabolism
621,ALS_B,HYI,-0.1,45,cardiac,propanoate metabolism
622,ALS_B,IMPACT,0.2,32,cardiac,MAPK
623,ALS_B,C2orf49,0.3,15,cardiac,Wnt signalling
624,ALS_B,HDAC11,-0.6,46,skeletal,Wnt signalling
625,ALS_B,CCN4,-0.2,51,cardiac,apoptosis
626,ALS_B,MKLN1,0.6,80,smooth,synthesis and degradation of ketone bodies
627,ALS_B,GPRC5B,0.3,92,smooth,fatty acid degradation
628,ALS_B,RPS6KB1,0.6,42,cardiac,synthesis and degradation of ketone bodies
629,ALS_B,PSMA3,-0.1,52,skeletal,propanoate metabolism
630,ALS_B,JARID2,-0.3,93,smooth,fatty acid degradation
631,ALS_B,ODF2,0.3,55,cardiac,propanoate metabolism
632,ALS_B,MON2,NA,55,smooth,synthesis and degradation of ketone bodies
633,ALS_B,PDLIM2,-0.1,50,cardiac,focal adhesion
634,ALS_B,WAC,0.5,87,smooth,cancer pathways
635,ALS_B,FLCN,-0.2,32,skeletal,focal adhesion
636,ALS_B,ATF6,0.4,57,smooth,cancer pathways
637,ALS_B,TRAFD1,-0.2,63,smooth,citrate cycle
638,ALS_B,BICD1,0.9,82,skeletal,focal adhesion
639,ALS_B,ANP32A,-0.2,58,skeletal,cancer pathways
640,ALS_B,KDSR,0.3,35,cardiac,synthesis and degradation of ketone bodies
641,ALS_B,FBXO9,0.1,64,smooth,synthesis and degradation of ketone bodies
642,ALS_B,UBQLN2,0.3,31,cardiac,Wnt signalling
643,ALS_B,ZFX,0.5,15,cardiac,synthesis and degradation of ketone bodies
644,ALS_B,CPLX2,-0.3,64,smooth,fatty acid degradation
645,ALS_B,CLPX,0.4,56,smooth,Wnt signalling
646,ALS_B,SGCB,0.5,79,cardiac,pyruvate metabolism
647,ALS_B,SEMA5A,NA,94,cardiac,fatty acid degradation
648,ALS_B,PTPRB,0.3,63,smooth,pyruvate metabolism
649,ALS_B,TMEM33,0.7,5,smooth,Wnt signalling
650,ALS_B,SMC1A,0.1,72,skeletal,MAPK
651,AQM_B,NF1,-0.1,72,skeletal,synthesis and degradation of ketone bodies
652,AQM_B,UEVLD,0.2,50,cardiac,cancer pathways
653,AQM_B,CDC37L1,0.2,70,smooth,focal adhesion
654,AQM_B,HOXD10,NA,75,smooth,fatty acid degradation
655,AQM_B,NNT,-0.5,14,skeletal,MAPK
656,AQM_B,HUWE1,0.2,52,skeletal,apoptosis
657,AQM_B,GJA5,-0.2,20,skeletal,pyruvate metabolism
658,AQM_B,SPCS3,0.4,74,smooth,focal adhesion
659,AQM_B,DOT1L,NA,67,cardiac,apoptosis
660,AQM_B,ATP6V0E1,0.8,33,smooth,cancer pathways
661,AQM_B,XAF1,0.1,43,cardiac,cancer pathways
662,AQM_B,MAFG,NA,81,cardiac,apoptosis
663,AQM_B,AAK1,0.9,23,skeletal,pyruvate metabolism
664,AQM_B,TM2D3,NA,24,smooth,cancer pathways
665,AQM_B,SSR3,0.7,94,smooth,citrate cycle
666,AQM_B,ZNF281,0.4,96,skeletal,fatty acid degradation
667,AQM_B,JAM2,-0.1,92,cardiac,pyruvate metabolism
668,AQM_B,CDC23,0.2,90,cardiac,focal adhesion
669,AQM_B,PLN,-1.3,61,smooth,synthesis and degradation of ketone bodies
670,AQM_B,PGP,-0.7,42,cardiac,propanoate metabolism
671,AQM_B,HYI,-0.1,60,cardiac,focal adhesion
672,AQM_B,IMPACT,0.6,38,cardiac,citrate cycle
673,AQM_B,C2orf49,0.4,62,smooth,synthesis and degradation of ketone bodies
674,AQM_B,HDAC11,-0.6,72,smooth,citrate cycle
675,AQM_B,CCN4,-0.3,39,smooth,Wnt signalling
676,AQM_B,MKLN1,1.1,51,skeletal,focal adhesion
677,AQM_B,GPRC5B,-0.3,56,skeletal,pyruvate metabolism
678,AQM_B,RPS6KB1,0.8,12,smooth,citrate cycle
679,AQM_B,PSMA3,-0.2,63,smooth,Wnt signalling
680,AQM_B,JARID2,-0.3,96,cardiac,Wnt signalling
681,AQM_B,ODF2,0.6,73,skeletal,pyruvate metabolism
682,AQM_B,MON2,-0.2,22,cardiac,MAPK
683,AQM_B,PDLIM2,-0.1,2,cardiac,pyruvate metabolism
684,AQM_B,WAC,1,37,smooth,synthesis and degradation of ketone bodies
685,AQM_B,FLCN,0.1,15,smooth,apoptosis
686,AQM_B,ATF6,0.4,55,skeletal,cancer pathways
687,AQM_B,TRAFD1,-0.1,28,smooth,MAPK
688,AQM_B,BICD1,0.2,77,cardiac,pyruvate metabolism
689,AQM_B,ANP32A,NA,36,cardiac,cancer pathways
690,AQM_B,KDSR,0.6,60,cardiac,citrate cycle
691,AQM_B,FBXO9,-0.3,73,smooth,cancer pathways
692,AQM_B,UBQLN2,0.2,93,smooth,apoptosis
693,AQM_B,ZFX,0.5,56,smooth,apoptosis
694,AQM_B,CPLX2,NA,31,cardiac,focal adhesion
695,AQM_B,CLPX,0.2,13,cardiac,propanoate metabolism
696,AQM_B,SGCB,0.2,91,cardiac,apoptosis
697,AQM_B,SEMA5A,-0.2,50,cardiac,fatty acid degradation
698,AQM_B,PTPRB,NA,30,cardiac,apoptosis
699,AQM_B,TMEM33,0.8,90,cardiac,Wnt signalling
700,AQM_B,SMC1A,0.1,70,skeletal,apoptosis
701,BMD_B,NF1,NA,64,smooth,citrate cycle
702,BMD_B,UEVLD,0.1,33,smooth,apoptosis
703,BMD_B,CDC37L1,0.2,55,skeletal,citrate cycle
704,BMD_B,HOXD10,-0.2,86,skeletal,synthesis and degradation of ketone bodies
705,BMD_B,NNT,-0.8,50,smooth,citrate cycle
706,BMD_B,HUWE1,NA,56,skeletal,Wnt signalling
707,BMD_B,GJA5,0.3,96,cardiac,synthesis and degradation of ketone bodies
708,BMD_B,SPCS3,0.2,13,skeletal,pyruvate metabolism
709,BMD_B,DOT1L,0.1,75,smooth,fatty acid degradation
710,BMD_B,ATP6V0E1,0.5,53,cardiac,Wnt signalling
711,BMD_B,XAF1,-0.1,50,cardiac,cancer pathways
712,BMD_B,MAFG,0.2,74,smooth,Wnt signalling
713,BMD_B,AAK1,0.5,28,smooth,synthesis and degradation of ketone bodies
714,BMD_B,TM2D3,0.1,29,smooth,Wnt signalling
715,BMD_B,SSR3,0.1,75,cardiac,focal adhesion
716,BMD_B,ZNF281,-0.1,15,smooth,citrate cycle
717,BMD_B,JAM2,0.3,98,cardiac,apoptosis
718,BMD_B,CDC23,NA,93,smooth,cancer pathways
719,BMD_B,PLN,-1.1,52,smooth,cancer pathways
720,BMD_B,PGP,-0.4,67,skeletal,cancer pathways
721,BMD_B,HYI,0.1,10,smooth,MAPK
722,BMD_B,IMPACT,-0.1,43,cardiac,Wnt signalling
723,BMD_B,C2orf49,-0.2,45,smooth,cancer pathways
724,BMD_B,HDAC11,-0.2,56,skeletal,propanoate metabolism
725,BMD_B,CCN4,-0.1,81,cardiac,Wnt signalling
726,BMD_B,MKLN1,-0.4,14,cardiac,Wnt signalling
727,BMD_B,GPRC5B,0.3,78,skeletal,Wnt signalling
728,BMD_B,RPS6KB1,-0.3,2,skeletal,propanoate metabolism
729,BMD_B,PSMA3,-0.2,88,cardiac,fatty acid degradation
730,BMD_B,JARID2,-0.1,58,skeletal,cancer pathways
731,BMD_B,ODF2,0.2,70,skeletal,synthesis and degradation of ketone bodies
732,BMD_B,MON2,NA,25,cardiac,Wnt signalling
733,BMD_B,PDLIM2,0.1,45,skeletal,propanoate metabolism
734,BMD_B,WAC,-0.1,94,cardiac,Wnt signalling
735,BMD_B,FLCN,-0.1,24,smooth,MAPK
736,BMD_B,ATF6,0.4,40,skeletal,Wnt signalling
737,BMD_B,TRAFD1,-0.2,38,skeletal,fatty acid degradation
738,BMD_B,BICD1,0.7,33,skeletal,MAPK
739,BMD_B,ANP32A,0.1,91,skeletal,fatty acid degradation
740,BMD_B,KDSR,0.3,45,cardiac,cancer pathways
741,BMD_B,FBXO9,NA,76,smooth,propanoate metabolism
742,BMD_B,UBQLN2,NA,93,smooth,Wnt signalling
743,BMD_B,ZFX,-0.1,70,smooth,focal adhesion
744,BMD_B,CPLX2,NA,31,cardiac,MAPK
745,BMD_B,CLPX,-0.2,66,cardiac,focal adhesion
746,BMD_B,SGCB,NA,92,skeletal,Wnt signalling
747,BMD_B,SEMA5A,-0.1,12,skeletal,focal adhesion
748,BMD_B,PTPRB,0.2,88,skeletal,focal adhesion
749,BMD_B,TMEM33,0.2,6,skeletal,fatty acid degradation
750,BMD_B,SMC1A,-0.2,60,smooth,propanoate metabolism
751,DMD_B,NF1,0.1,92,cardiac,MAPK
752,DMD_B,UEVLD,0.1,88,cardiac,pyruvate metabolism
753,DMD_B,CDC37L1,-0.4,17,skeletal,pyruvate metabolism
754,DMD_B,HOXD10,-0.1,94,smooth,focal adhesion
755,DMD_B,NNT,-0.6,76,cardiac,apoptosis
756,DMD_B,HUWE1,NA,4,smooth,fatty acid degradation
757,DMD_B,GJA5,0.1,78,smooth,MAPK
758,DMD_B,SPCS3,0.2,35,cardiac,pyruvate metabolism
759,DMD_B,DOT1L,NA,50,cardiac,fatty acid degradation
760,DMD_B,ATP6V0E1,0.6,66,cardiac,focal adhesion
761,DMD_B,XAF1,0.7,83,cardiac,apoptosis
762,DMD_B,MAFG,-0.2,68,cardiac,fatty acid degradation
763,DMD_B,AAK1,0.4,73,skeletal,cancer pathways
764,DMD_B,TM2D3,NA,22,smooth,citrate cycle
765,DMD_B,SSR3,0.4,53,skeletal,fatty acid degradation
766,DMD_B,ZNF281,NA,1,smooth,focal adhesion
767,DMD_B,JAM2,1.1,76,skeletal,apoptosis
768,DMD_B,CDC23,0.2,41,smooth,fatty acid degradation
769,DMD_B,PLN,-0.7,30,smooth,citrate cycle
770,DMD_B,PGP,-0.9,39,cardiac,pyruvate metabolism
771,DMD_B,HYI,-0.1,1,smooth,MAPK
772,DMD_B,IMPACT,0.1,52,cardiac,Wnt signalling
773,DMD_B,C2orf49,NA,28,cardiac,citrate cycle
774,DMD_B,HDAC11,-0.3,87,smooth,apoptosis
775,DMD_B,CCN4,NA,49,skeletal,citrate cycle
776,DMD_B,MKLN1,0.2,48,skeletal,MAPK
777,DMD_B,GPRC5B,NA,31,smooth,apoptosis
778,DMD_B,RPS6KB1,0.1,97,skeletal,citrate cycle
779,DMD_B,PSMA3,-0.2,1,skeletal,MAPK
780,DMD_B,JARID2,-0.3,35,skeletal,Wnt signalling
781,DMD_B,ODF2,0.4,100,skeletal,fatty acid degradation
782,DMD_B,MON2,NA,44,skeletal,pyruvate metabolism
783,DMD_B,PDLIM2,-0.1,2,smooth,focal adhesion
784,DMD_B,WAC,0.5,20,smooth,cancer pathways
785,DMD_B,FLCN,-0.1,71,smooth,Wnt signalling
786,DMD_B,ATF6,0.5,24,smooth,citrate cycle
787,DMD_B,TRAFD1,-0.2,85,skeletal,cancer pathways
788,DMD_B,BICD1,0.5,38,skeletal,fatty acid degradation
789,DMD_B,ANP32A,NA,4,cardiac,citrate cycle
790,DMD_B,KDSR,0.6,86,cardiac,Wnt signalling
791,DMD_B,FBXO9,0.1,31,smooth,fatty acid degradation
792,DMD_B,UBQLN2,0.1,33,smooth,apoptosis
793,DMD_B,ZFX,NA,95,skeletal,apoptosis
794,DMD_B,CPLX2,-0.1,30,smooth,fatty acid degradation
795,DMD_B,CLPX,-0.2,44,smooth,pyruvate metabolism
796,DMD_B,SGCB,-0.2,13,skeletal,cancer pathways
797,DMD_B,SEMA5A,0.1,57,smooth,synthesis and degradation of ketone bodies
798,DMD_B,PTPRB,0.3,78,skeletal,pyruvate metabolism
799,DMD_B,TMEM33,0.4,87,smooth,fatty acid degradation
800,DMD_B,SMC1A,-0.1,96,smooth,citrate cycle
801,EDMD.AD_B,NF1,0.2,3,cardiac,Wnt signalling
802,EDMD.AD_B,UEVLD,0.1,47,smooth,Wnt signalling
803,EDMD.AD_B,CDC37L1,0.4,46,skeletal,propanoate metabolism
804,EDMD.AD_B,HOXD10,-0.1,13,skeletal,Wnt signalling
805,EDMD.AD_B,NNT,-0.2,0,smooth,cancer pathways
806,EDMD.AD_B,HUWE1,NA,82,smooth,pyruvate metabolism
807,EDMD.AD_B,GJA5,-0.1,51,cardiac,MAPK
808,EDMD.AD_B,SPCS3,NA,81,skeletal,pyruvate metabolism
809,EDMD.AD_B,DOT1L,0.2,93,skeletal,Wnt signalling
810,EDMD.AD_B,ATP6V0E1,0.8,22,smooth,fatty acid degradation
811,EDMD.AD_B,XAF1,0.3,75,skeletal,Wnt signalling
812,EDMD.AD_B,MAFG,-0.3,23,skeletal,Wnt signalling
813,EDMD.AD_B,AAK1,0.5,87,skeletal,synthesis and degradation of ketone bodies
814,EDMD.AD_B,TM2D3,NA,27,skeletal,fatty acid degradation
815,EDMD.AD_B,SSR3,0.3,85,skeletal,focal adhesion
816,EDMD.AD_B,ZNF281,0.2,5,skeletal,focal adhesion
817,EDMD.AD_B,JAM2,0.7,68,skeletal,focal adhesion
818,EDMD.AD_B,CDC23,0.4,74,skeletal,focal adhesion
819,EDMD.AD_B,PLN,-0.6,29,skeletal,citrate cycle
820,EDMD.AD_B,PGP,-0.7,74,cardiac,apoptosis
821,EDMD.AD_B,HYI,NA,77,smooth,fatty acid degradation
822,EDMD.AD_B,IMPACT,NA,91,smooth,Wnt signalling
823,EDMD.AD_B,C2orf49,0.1,87,skeletal,fatty acid degradation
824,EDMD.AD_B,HDAC11,-0.5,49,skeletal,cancer pathways
825,EDMD.AD_B,CCN4,NA,93,smooth,fatty acid degradation
826,EDMD.AD_B,MKLN1,0.6,21,smooth,MAPK
827,EDMD.AD_B,GPRC5B,-0.3,56,skeletal,focal adhesion
828,EDMD.AD_B,RPS6KB1,0.3,83,skeletal,fatty acid degradation
829,EDMD.AD_B,PSMA3,0.1,59,smooth,propanoate metabolism
830,EDMD.AD_B,JARID2,-0.2,54,skeletal,apoptosis
831,EDMD.AD_B,ODF2,0.4,72,cardiac,MAPK
832,EDMD.AD_B,MON2,NA,11,cardiac,fatty acid degradation
833,EDMD.AD_B,PDLIM2,-0.2,29,cardiac,focal adhesion
834,EDMD.AD_B,WAC,0.6,12,cardiac,Wnt signalling
835,EDMD.AD_B,FLCN,-0.2,45,skeletal,cancer pathways
836,EDMD.AD_B,ATF6,0.5,15,cardiac,propanoate metabolism
837,EDMD.AD_B,TRAFD1,0.1,87,smooth,propanoate metabolism
838,EDMD.AD_B,BICD1,0.7,70,cardiac,citrate cycle
839,EDMD.AD_B,ANP32A,-0.1,94,cardiac,pyruvate metabolism
840,EDMD.AD_B,KDSR,0.8,70,smooth,pyruvate metabolism
841,EDMD.AD_B,FBXO9,NA,13,skeletal,focal adhesion
842,EDMD.AD_B,UBQLN2,NA,79,skeletal,propanoate metabolism
843,EDMD.AD_B,ZFX,0.3,50,skeletal,focal adhesion
844,EDMD.AD_B,CPLX2,-0.2,21,skeletal,cancer pathways
845,EDMD.AD_B,CLPX,NA,37,cardiac,fatty acid degradation
846,EDMD.AD_B,SGCB,-0.1,21,smooth,citrate cycle
847,EDMD.AD_B,SEMA5A,0.2,5,cardiac,fatty acid degradation
848,EDMD.AD_B,PTPRB,0.3,83,cardiac,propanoate metabolism
849,EDMD.AD_B,TMEM33,0.6,40,skeletal,fatty acid degradation
850,EDMD.AD_B,SMC1A,NA,97,smooth,synthesis and degradation of ketone bodies
851,EDMD.XR_B,NF1,NA,68,cardiac,focal adhesion
852,EDMD.XR_B,UEVLD,NA,39,cardiac,synthesis and degradation of ketone bodies
853,EDMD.XR_B,CDC37L1,0.6,70,cardiac,apoptosis
854,EDMD.XR_B,HOXD10,NA,73,smooth,pyruvate metabolism
855,EDMD.XR_B,NNT,0.2,26,cardiac,focal adhesion
856,EDMD.XR_B,HUWE1,NA,92,cardiac,synthesis and degradation of ketone bodies
857,EDMD.XR_B,GJA5,-0.2,49,skeletal,citrate cycle
858,EDMD.XR_B,SPCS3,0.2,38,smooth,pyruvate metabolism
859,EDMD.XR_B,DOT1L,NA,2,smooth,fatty acid degradation
860,EDMD.XR_B,ATP6V0E1,0.5,80,skeletal,Wnt signalling
861,EDMD.XR_B,XAF1,0.1,16,skeletal,synthesis and degradation of ketone bodies
862,EDMD.XR_B,MAFG,NA,64,smooth,pyruvate metabolism
863,EDMD.XR_B,AAK1,0.5,73,skeletal,MAPK
864,EDMD.XR_B,TM2D3,0.3,78,cardiac,fatty acid degradation
865,EDMD.XR_B,SSR3,NA,32,cardiac,pyruvate metabolism
866,EDMD.XR_B,ZNF281,0.3,17,skeletal,focal adhesion
867,EDMD.XR_B,JAM2,NA,61,skeletal,citrate cycle
868,EDMD.XR_B,CDC23,NA,43,skeletal,cancer pathways
869,EDMD.XR_B,PLN,NA,88,smooth,focal adhesion
870,EDMD.XR_B,PGP,-0.1,57,smooth,fatty acid degradation
871,EDMD.XR_B,HYI,-0.2,28,cardiac,apoptosis
872,EDMD.XR_B,IMPACT,-0.1,25,skeletal,cancer pathways
873,EDMD.XR_B,C2orf49,0.2,15,smooth,pyruvate metabolism
874,EDMD.XR_B,HDAC11,-0.1,81,smooth,propanoate metabolism
875,EDMD.XR_B,CCN4,NA,28,smooth,synthesis and degradation of ketone bodies
876,EDMD.XR_B,MKLN1,0.3,99,smooth,pyruvate metabolism
877,EDMD.XR_B,GPRC5B,0.1,78,smooth,Wnt signalling
878,EDMD.XR_B,RPS6KB1,0.2,58,skeletal,pyruvate metabolism
879,EDMD.XR_B,PSMA3,NA,92,smooth,MAPK
880,EDMD.XR_B,JARID2,-0.3,37,smooth,focal adhesion
881,EDMD.XR_B,ODF2,NA,54,cardiac,Wnt signalling
882,EDMD.XR_B,MON2,NA,88,skeletal,focal adhesion
883,EDMD.XR_B,PDLIM2,-0.2,53,cardiac,synthesis and degradation of ketone bodies
884,EDMD.XR_B,WAC,0.2,17,smooth,synthesis and degradation of ketone bodies
885,EDMD.XR_B,FLCN,-0.2,96,skeletal,propanoate metabolism
886,EDMD.XR_B,ATF6,0.4,61,skeletal,fatty acid degradation
887,EDMD.XR_B,TRAFD1,NA,23,smooth,propanoate metabolism
888,EDMD.XR_B,BICD1,0.6,1,cardiac,propanoate metabolism
889,EDMD.XR_B,ANP32A,-0.2,100,cardiac,propanoate metabolism
890,EDMD.XR_B,KDSR,0.2,67,cardiac,MAPK
891,EDMD.XR_B,FBXO9,0.2,81,skeletal,fatty acid degradation
892,EDMD.XR_B,UBQLN2,NA,6,skeletal,citrate cycle
893,EDMD.XR_B,ZFX,0.2,98,smooth,apoptosis
894,EDMD.XR_B,CPLX2,NA,48,smooth,focal adhesion
895,EDMD.XR_B,CLPX,0.2,42,smooth,Wnt signalling
896,EDMD.XR_B,SGCB,0.1,92,smooth,synthesis and degradation of ketone bodies
897,EDMD.XR_B,SEMA5A,NA,16,cardiac,fatty acid degradation
898,EDMD.XR_B,PTPRB,-0.1,25,cardiac,propanoate metabolism
899,EDMD.XR_B,TMEM33,0.4,89,cardiac,citrate cycle
900,EDMD.XR_B,SMC1A,NA,85,skeletal,Wnt signalling
901,FSHD_B,NF1,NA,62,skeletal,Wnt signalling
902,FSHD_B,UEVLD,0.5,44,skeletal,citrate cycle
903,FSHD_B,CDC37L1,0.4,54,cardiac,pyruvate metabolism
904,FSHD_B,HOXD10,-0.1,85,smooth,synthesis and degradation of ketone bodies
905,FSHD_B,NNT,0.3,15,skeletal,focal adhesion
906,FSHD_B,HUWE1,0.1,45,smooth,focal adhesion
907,FSHD_B,GJA5,-0.2,32,skeletal,pyruvate metabolism
908,FSHD_B,SPCS3,NA,43,smooth,Wnt signalling
909,FSHD_B,DOT1L,0.4,92,cardiac,fatty acid degradation
910,FSHD_B,ATP6V0E1,0.7,85,cardiac,focal adhesion
911,FSHD_B,XAF1,0.5,97,cardiac,citrate cycle
912,FSHD_B,MAFG,-0.2,44,skeletal,synthesis and degradation of ketone bodies
913,FSHD_B,AAK1,0.6,52,skeletal,fatty acid degradation
914,FSHD_B,TM2D3,0.2,94,skeletal,Wnt signalling
915,FSHD_B,SSR3,0.5,35,cardiac,citrate cycle
916,FSHD_B,ZNF281,0.4,38,cardiac,fatty acid degradation
917,FSHD_B,JAM2,0.6,56,cardiac,cancer pathways
918,FSHD_B,CDC23,0.1,22,smooth,synthesis and degradation of ketone bodies
919,FSHD_B,PLN,0.2,29,cardiac,citrate cycle
920,FSHD_B,PGP,0.1,41,skeletal,synthesis and degradation of ketone bodies
921,FSHD_B,HYI,NA,30,smooth,apoptosis
922,FSHD_B,IMPACT,0.2,88,skeletal,cancer pathways
923,FSHD_B,C2orf49,0.6,70,smooth,citrate cycle
924,FSHD_B,HDAC11,NA,1,skeletal,pyruvate metabolism
925,FSHD_B,CCN4,-0.3,59,smooth,fatty acid degradation
926,FSHD_B,MKLN1,0.6,16,skeletal,focal adhesion
927,FSHD_B,GPRC5B,0.4,5,skeletal,Wnt signalling
928,FSHD_B,RPS6KB1,0.5,15,smooth,focal adhesion
929,FSHD_B,PSMA3,NA,6,skeletal,pyruvate metabolism
930,FSHD_B,JARID2,-0.1,48,cardiac,propanoate metabolism
931,FSHD_B,ODF2,0.1,82,cardiac,focal adhesion
932,FSHD_B,MON2,-0.1,99,smooth,apoptosis
933,FSHD_B,PDLIM2,-0.1,22,skeletal,cancer pathways
934,FSHD_B,WAC,0.8,79,smooth,pyruvate metabolism
935,FSHD_B,FLCN,-0.2,64,cardiac,cancer pathways
936,FSHD_B,ATF6,0.5,24,smooth,focal adhesion
937,FSHD_B,TRAFD1,-0.1,5,cardiac,Wnt signalling
938,FSHD_B,BICD1,0.4,48,cardiac,fatty acid degradation
939,FSHD_B,ANP32A,NA,5,skeletal,MAPK
940,FSHD_B,KDSR,0.9,70,smooth,cancer pathways
941,FSHD_B,FBXO9,-0.1,1,smooth,MAPK
942,FSHD_B,UBQLN2,0.3,9,smooth,apoptosis
943,FSHD_B,ZFX,0.4,47,smooth,cancer pathways
944,FSHD_B,CPLX2,-0.2,45,cardiac,focal adhesion
945,FSHD_B,CLPX,0.2,32,cardiac,citrate cycle
946,FSHD_B,SGCB,0.3,71,skeletal,cancer pathways
947,FSHD_B,SEMA5A,-0.1,75,skeletal,focal adhesion
948,FSHD_B,PTPRB,0.6,57,skeletal,synthesis and degradation of ketone bodies
949,FSHD_B,TMEM33,0.4,100,smooth,focal adhesion
950,FSHD_B,SMC1A,-0.1,49,cardiac,citrate cycle
951,HSP_B,NF1,NA,51,skeletal,synthesis and degradation of ketone bodies
952,HSP_B,UEVLD,NA,48,cardiac,Wnt signalling
953,HSP_B,CDC37L1,-0.8,99,smooth,fatty acid degradation
954,HSP_B,HOXD10,NA,63,cardiac,citrate cycle
955,HSP_B,NNT,-0.8,64,smooth,propanoate metabolism
956,HSP_B,HUWE1,NA,100,smooth,Wnt signalling
957,HSP_B,GJA5,0.3,42,smooth,citrate cycle
958,HSP_B,SPCS3,NA,100,skeletal,Wnt signalling
959,HSP_B,DOT1L,NA,39,skeletal,focal adhesion
960,HSP_B,ATP6V0E1,-0.4,54,cardiac,focal adhesion
961,HSP_B,XAF1,-0.3,66,smooth,synthesis and degradation of ketone bodies
962,HSP_B,MAFG,0.4,85,smooth,Wnt signalling
963,HSP_B,AAK1,-0.1,48,cardiac,Wnt signalling
964,HSP_B,TM2D3,-0.2,94,cardiac,fatty acid degradation
965,HSP_B,SSR3,-0.4,4,skeletal,synthesis and degradation of ketone bodies
966,HSP_B,ZNF281,-0.2,60,cardiac,cancer pathways
967,HSP_B,JAM2,-0.4,69,skeletal,MAPK
968,HSP_B,CDC23,NA,73,smooth,MAPK
969,HSP_B,PLN,-0.7,18,cardiac,pyruvate metabolism
970,HSP_B,PGP,0.3,0,cardiac,pyruvate metabolism
971,HSP_B,HYI,0.5,72,smooth,MAPK
972,HSP_B,IMPACT,-0.6,26,smooth,MAPK
973,HSP_B,C2orf49,0.1,65,cardiac,apoptosis
974,HSP_B,HDAC11,0.6,44,skeletal,Wnt signalling
975,HSP_B,CCN4,NA,69,skeletal,pyruvate metabolism
976,HSP_B,MKLN1,-0.7,72,skeletal,propanoate metabolism
977,HSP_B,GPRC5B,-0.1,29,skeletal,apoptosis
978,HSP_B,RPS6KB1,-0.8,23,smooth,synthesis and degradation of ketone bodies
979,HSP_B,PSMA3,NA,91,cardiac,cancer pathways
980,HSP_B,JARID2,-0.1,66,smooth,apoptosis
981,HSP_B,ODF2,NA,38,skeletal,propanoate metabolism
982,HSP_B,MON2,NA,69,cardiac,MAPK
983,HSP_B,PDLIM2,NA,0,smooth,cancer pathways
984,HSP_B,WAC,-0.4,57,cardiac,fatty acid degradation
985,HSP_B,FLCN,0.3,31,smooth,cancer pathways
986,HSP_B,ATF6,-0.2,98,cardiac,fatty acid degradation
987,HSP_B,TRAFD1,NA,77,skeletal,synthesis and degradation of ketone bodies
988,HSP_B,BICD1,-0.3,6,smooth,citrate cycle
989,HSP_B,ANP32A,0.3,90,skeletal,Wnt signalling
990,HSP_B,KDSR,-0.2,8,cardiac,propanoate metabolism
991,HSP_B,FBXO9,-0.3,60,smooth,cancer pathways
992,HSP_B,UBQLN2,NA,28,cardiac,pyruvate metabolism
993,HSP_B,ZFX,-0.2,76,cardiac,apoptosis
994,HSP_B,CPLX2,NA,86,skeletal,synthesis and degradation of ketone bodies
995,HSP_B,CLPX,-0.3,94,smooth,Wnt signalling
996,HSP_B,SGCB,-0.1,21,skeletal,synthesis and degradation of ketone bodies
997,HSP_B,SEMA5A,NA,80,smooth,synthesis and degradation of ketone bodies
998,HSP_B,PTPRB,-0.5,58,cardiac,focal adhesion
999,HSP_B,TMEM33,-0.3,11,cardiac,focal adhesion
1000,HSP_B,SMC1A,NA,31,cardiac,pyruvate metabolism
1001,JDM_B,NF1,0.1,42,skeletal,propanoate metabolism
1002,JDM_B,UEVLD,0.3,54,skeletal,Wnt signalling
1003,JDM_B,CDC37L1,0.5,4,cardiac,MAPK
1004,JDM_B,HOXD10,NA,86,smooth,fatty acid degradation
1005,JDM_B,NNT,-0.3,80,smooth,citrate cycle
1006,JDM_B,HUWE1,0.1,77,smooth,Wnt signalling
1007,JDM_B,GJA5,-0.3,71,smooth,fatty acid degradation
1008,JDM_B,SPCS3,0.6,73,cardiac,citrate cycle
1009,JDM_B,DOT1L,0.8,24,cardiac,Wnt signalling
1010,JDM_B,ATP6V0E1,0.9,59,smooth,citrate cycle
1011,JDM_B,XAF1,3.4,73,skeletal,apoptosis
1012,JDM_B,MAFG,-0.4,56,skeletal,synthesis and degradation of ketone bodies
1013,JDM_B,AAK1,0.7,91,skeletal,synthesis and degradation of ketone bodies
1014,JDM_B,TM2D3,-0.3,82,smooth,citrate cycle
1015,JDM_B,SSR3,0.9,19,skeletal,fatty acid degradation
1016,JDM_B,ZNF281,0.8,33,cardiac,propanoate metabolism
1017,JDM_B,JAM2,0.8,51,smooth,cancer pathways
1018,JDM_B,CDC23,0.3,36,skeletal,propanoate metabolism
1019,JDM_B,PLN,-0.3,14,skeletal,propanoate metabolism
1020,JDM_B,PGP,-0.2,26,smooth,cancer pathways
1021,JDM_B,HYI,-0.2,72,smooth,focal adhesion
1022,JDM_B,IMPACT,0.4,61,smooth,synthesis and degradation of ketone bodies
1023,JDM_B,C2orf49,0.6,59,cardiac,pyruvate metabolism
1024,JDM_B,HDAC11,-0.2,41,smooth,propanoate metabolism
1025,JDM_B,CCN4,-0.3,65,smooth,focal adhesion
1026,JDM_B,MKLN1,0.9,73,smooth,Wnt signalling
1027,JDM_B,GPRC5B,NA,3,skeletal,MAPK
1028,JDM_B,RPS6KB1,0.8,69,skeletal,pyruvate metabolism
1029,JDM_B,PSMA3,-0.1,48,smooth,apoptosis
1030,JDM_B,JARID2,-0.2,40,skeletal,propanoate metabolism
1031,JDM_B,ODF2,0.4,2,cardiac,citrate cycle
1032,JDM_B,MON2,-0.1,14,smooth,pyruvate metabolism
1033,JDM_B,PDLIM2,-0.2,52,cardiac,citrate cycle
1034,JDM_B,WAC,1.3,10,skeletal,propanoate metabolism
1035,JDM_B,FLCN,NA,42,cardiac,MAPK
1036,JDM_B,ATF6,0.7,42,skeletal,focal adhesion
1037,JDM_B,TRAFD1,0.2,91,smooth,Wnt signalling
1038,JDM_B,BICD1,NA,26,skeletal,cancer pathways
1039,JDM_B,ANP32A,-0.1,72,cardiac,cancer pathways
1040,JDM_B,KDSR,0.8,75,skeletal,propanoate metabolism
1041,JDM_B,FBXO9,-0.2,39,cardiac,MAPK
1042,JDM_B,UBQLN2,0.3,7,smooth,MAPK
1043,JDM_B,ZFX,0.8,6,smooth,MAPK
1044,JDM_B,CPLX2,-0.3,85,smooth,focal adhesion
1045,JDM_B,CLPX,0.2,14,smooth,synthesis and degradation of ketone bodies
1046,JDM_B,SGCB,0.1,80,cardiac,Wnt signalling
1047,JDM_B,SEMA5A,-0.1,90,skeletal,apoptosis
1048,JDM_B,PTPRB,0.8,100,cardiac,apoptosis
1049,JDM_B,TMEM33,0.6,60,cardiac,MAPK
1050,JDM_B,SMC1A,-0.1,7,skeletal,MAPK
1051,LGMD2A_B,NF1,NA,26,skeletal,Wnt signalling
1052,LGMD2A_B,UEVLD,-0.1,29,cardiac,apoptosis
1053,LGMD2A_B,CDC37L1,-0.2,19,skeletal,MAPK
1054,LGMD2A_B,HOXD10,NA,99,smooth,apoptosis
1055,LGMD2A_B,NNT,-0.8,4,cardiac,synthesis and degradation of ketone bodies
1056,LGMD2A_B,HUWE1,NA,93,smooth,synthesis and degradation of ketone bodies
1057,LGMD2A_B,GJA5,0.2,92,cardiac,pyruvate metabolism
1058,LGMD2A_B,SPCS3,NA,49,cardiac,synthesis and degradation of ketone bodies
1059,LGMD2A_B,DOT1L,NA,87,cardiac,propanoate metabolism
1060,LGMD2A_B,ATP6V0E1,0.1,0,skeletal,MAPK
1061,LGMD2A_B,XAF1,0.2,65,skeletal,citrate cycle
1062,LGMD2A_B,MAFG,0.1,12,skeletal,fatty acid degradation
1063,LGMD2A_B,AAK1,0.2,65,cardiac,propanoate metabolism
1064,LGMD2A_B,TM2D3,NA,30,cardiac,citrate cycle
1065,LGMD2A_B,SSR3,0.1,53,skeletal,propanoate metabolism
1066,LGMD2A_B,ZNF281,-0.1,55,skeletal,propanoate metabolism
1067,LGMD2A_B,JAM2,0.4,7,smooth,pyruvate metabolism
1068,LGMD2A_B,CDC23,NA,27,smooth,fatty acid degradation
1069,LGMD2A_B,PLN,-1.1,49,smooth,synthesis and degradation of ketone bodies
1070,LGMD2A_B,PGP,-0.5,89,cardiac,cancer pathways
1071,LGMD2A_B,HYI,0.2,89,smooth,apoptosis
1072,LGMD2A_B,IMPACT,-0.1,21,skeletal,citrate cycle
1073,LGMD2A_B,C2orf49,-0.1,80,cardiac,synthesis and degradation of ketone bodies
1074,LGMD2A_B,HDAC11,-0.3,74,smooth,synthesis and degradation of ketone bodies
1075,LGMD2A_B,CCN4,-0.1,59,skeletal,Wnt signalling
1076,LGMD2A_B,MKLN1,NA,0,smooth,MAPK
1077,LGMD2A_B,GPRC5B,0.1,14,cardiac,propanoate metabolism
1078,LGMD2A_B,RPS6KB1,-0.2,37,skeletal,apoptosis
1079,LGMD2A_B,PSMA3,0.1,18,skeletal,fatty acid degradation
1080,LGMD2A_B,JARID2,-0.1,45,cardiac,synthesis and degradation of ketone bodies
1081,LGMD2A_B,ODF2,0.3,87,skeletal,pyruvate metabolism
1082,LGMD2A_B,MON2,-0.1,13,smooth,focal adhesion
1083,LGMD2A_B,PDLIM2,NA,5,cardiac,fatty acid degradation
1084,LGMD2A_B,WAC,0.1,49,cardiac,MAPK
1085,LGMD2A_B,FLCN,-0.1,25,skeletal,cancer pathways
1086,LGMD2A_B,ATF6,0.3,39,smooth,Wnt signalling
1087,LGMD2A_B,TRAFD1,-0.1,96,smooth,propanoate metabolism
1088,LGMD2A_B,BICD1,0.3,29,skeletal,cancer pathways
1089,LGMD2A_B,ANP32A,0.1,48,smooth,MAPK
1090,LGMD2A_B,KDSR,0.3,66,smooth,MAPK
1091,LGMD2A_B,FBXO9,-0.3,72,smooth,Wnt signalling
1092,LGMD2A_B,UBQLN2,NA,33,cardiac,cancer pathways
1093,LGMD2A_B,ZFX,-0.1,25,skeletal,apoptosis
1094,LGMD2A_B,CPLX2,NA,56,smooth,Wnt signalling
1095,LGMD2A_B,CLPX,-0.3,8,cardiac,citrate cycle
1096,LGMD2A_B,SGCB,NA,81,cardiac,synthesis and degradation of ketone bodies
1097,LGMD2A_B,SEMA5A,-0.1,49,smooth,synthesis and degradation of ketone bodies
1098,LGMD2A_B,PTPRB,-0.1,74,smooth,pyruvate metabolism
1099,LGMD2A_B,TMEM33,0.2,59,cardiac,MAPK
1100,LGMD2A_B,SMC1A,-0.1,61,smooth,propanoate metabolism
1101,LGMD2B_B,NF1,NA,60,cardiac,apoptosis
1102,LGMD2B_B,UEVLD,NA,17,cardiac,MAPK
1103,LGMD2B_B,CDC37L1,-0.1,75,smooth,cancer pathways
1104,LGMD2B_B,HOXD10,NA,14,smooth,citrate cycle
1105,LGMD2B_B,NNT,-0.8,58,cardiac,citrate cycle
1106,LGMD2B_B,HUWE1,NA,11,cardiac,Wnt signalling
1107,LGMD2B_B,GJA5,0.5,93,skeletal,focal adhesion
1108,LGMD2B_B,SPCS3,0.2,15,smooth,apoptosis
1109,LGMD2B_B,DOT1L,-0.1,55,smooth,pyruvate metabolism
1110,LGMD2B_B,ATP6V0E1,0.2,28,smooth,citrate cycle
1111,LGMD2B_B,XAF1,0.1,96,smooth,apoptosis
1112,LGMD2B_B,MAFG,0.3,46,cardiac,focal adhesion
1113,LGMD2B_B,AAK1,0.3,96,cardiac,pyruvate metabolism
1114,LGMD2B_B,TM2D3,NA,28,smooth,apoptosis
1115,LGMD2B_B,SSR3,0.2,49,skeletal,pyruvate metabolism
1116,LGMD2B_B,ZNF281,-0.1,33,smooth,focal adhesion
1117,LGMD2B_B,JAM2,0.2,4,skeletal,fatty acid degradation
1118,LGMD2B_B,CDC23,NA,92,skeletal,citrate cycle
1119,LGMD2B_B,PLN,-1.1,7,skeletal,citrate cycle
1120,LGMD2B_B,PGP,-0.4,27,smooth,citrate cycle
1121,LGMD2B_B,HYI,NA,94,skeletal,pyruvate metabolism
1122,LGMD2B_B,IMPACT,-0.2,14,skeletal,pyruvate metabolism
1123,LGMD2B_B,C2orf49,-0.4,59,cardiac,synthesis and degradation of ketone bodies
1124,LGMD2B_B,HDAC11,NA,41,smooth,cancer pathways
1125,LGMD2B_B,CCN4,-0.1,59,smooth,synthesis and degradation of ketone bodies
1126,LGMD2B_B,MKLN1,-0.2,6,smooth,MAPK
1127,LGMD2B_B,GPRC5B,NA,52,smooth,MAPK
1128,LGMD2B_B,RPS6KB1,-0.3,83,skeletal,propanoate metabolism
1129,LGMD2B_B,PSMA3,NA,76,smooth,synthesis and degradation of ketone bodies
1130,LGMD2B_B,JARID2,-0.2,81,cardiac,apoptosis
1131,LGMD2B_B,ODF2,0.2,82,cardiac,apoptosis
1132,LGMD2B_B,MON2,NA,14,smooth,synthesis and degradation of ketone bodies
1133,LGMD2B_B,PDLIM2,NA,96,smooth,propanoate metabolism
1134,LGMD2B_B,WAC,-0.2,19,cardiac,cancer pathways
1135,LGMD2B_B,FLCN,-0.1,30,cardiac,cancer pathways
1136,LGMD2B_B,ATF6,0.1,23,cardiac,Wnt signalling
1137,LGMD2B_B,TRAFD1,-0.3,2,smooth,synthesis and degradation of ketone bodies
1138,LGMD2B_B,BICD1,0.1,99,skeletal,cancer pathways
1139,LGMD2B_B,ANP32A,0.1,14,smooth,propanoate metabolism
1140,LGMD2B_B,KDSR,NA,100,skeletal,propanoate metabolism
1141,LGMD2B_B,FBXO9,-0.2,11,smooth,citrate cycle
1142,LGMD2B_B,UBQLN2,NA,26,cardiac,citrate cycle
1143,LGMD2B_B,ZFX,-0.1,51,skeletal,Wnt signalling
1144,LGMD2B_B,CPLX2,0.2,90,skeletal,fatty acid degradation
1145,LGMD2B_B,CLPX,-0.3,11,cardiac,apoptosis
1146,LGMD2B_B,SGCB,-0.3,45,smooth,MAPK
1147,LGMD2B_B,SEMA5A,-0.2,20,smooth,apoptosis
1148,LGMD2B_B,PTPRB,-0.3,87,skeletal,fatty acid degradation
1149,LGMD2B_B,TMEM33,0.1,37,cardiac,synthesis and degradation of ketone bodies
1150,LGMD2B_B,SMC1A,NA,74,skeletal,synthesis and degradation of ketone bodies
1151,LGMD2I_B,NF1,NA,66,cardiac,citrate cycle
1152,LGMD2I_B,UEVLD,0.1,20,smooth,synthesis and degradation of ketone bodies
1153,LGMD2I_B,CDC37L1,-0.1,11,cardiac,propanoate metabolism
1154,LGMD2I_B,HOXD10,-0.1,70,skeletal,focal adhesion
1155,LGMD2I_B,NNT,-0.6,44,skeletal,Wnt signalling
1156,LGMD2I_B,HUWE1,NA,41,smooth,fatty acid degradation
1157,LGMD2I_B,GJA5,0.3,73,smooth,focal adhesion
1158,LGMD2I_B,SPCS3,0.2,97,cardiac,cancer pathways
1159,LGMD2I_B,DOT1L,-0.1,80,smooth,MAPK
1160,LGMD2I_B,ATP6V0E1,0.1,98,cardiac,apoptosis
1161,LGMD2I_B,XAF1,0.1,28,cardiac,synthesis and degradation of ketone bodies
1162,LGMD2I_B,MAFG,0.2,56,skeletal,Wnt signalling
1163,LGMD2I_B,AAK1,0.4,66,cardiac,apoptosis
1164,LGMD2I_B,TM2D3,NA,79,cardiac,apoptosis
1165,LGMD2I_B,SSR3,NA,68,cardiac,pyruvate metabolism
1166,LGMD2I_B,ZNF281,-0.3,13,smooth,citrate cycle
1167,LGMD2I_B,JAM2,NA,38,smooth,synthesis and degradation of ketone bodies
1168,LGMD2I_B,CDC23,NA,54,cardiac,MAPK
1169,LGMD2I_B,PLN,-0.3,57,skeletal,MAPK
1170,LGMD2I_B,PGP,-0.4,29,cardiac,Wnt signalling
1171,LGMD2I_B,HYI,0.2,28,skeletal,citrate cycle
1172,LGMD2I_B,IMPACT,-0.1,42,smooth,citrate cycle
1173,LGMD2I_B,C2orf49,-0.2,36,skeletal,synthesis and degradation of ketone bodies
1174,LGMD2I_B,HDAC11,-0.1,34,skeletal,apoptosis
1175,LGMD2I_B,CCN4,NA,62,cardiac,citrate cycle
1176,LGMD2I_B,MKLN1,NA,25,skeletal,synthesis and degradation of ketone bodies
1177,LGMD2I_B,GPRC5B,0.1,71,smooth,apoptosis
1178,LGMD2I_B,RPS6KB1,-0.2,30,cardiac,synthesis and degradation of ketone bodies
1179,LGMD2I_B,PSMA3,-0.1,75,cardiac,MAPK
1180,LGMD2I_B,JARID2,-0.2,84,cardiac,synthesis and degradation of ketone bodies
1181,LGMD2I_B,ODF2,0.2,21,cardiac,propanoate metabolism
1182,LGMD2I_B,MON2,-0.2,46,cardiac,apoptosis
1183,LGMD2I_B,PDLIM2,0.1,45,skeletal,propanoate metabolism
1184,LGMD2I_B,WAC,0.1,9,cardiac,citrate cycle
1185,LGMD2I_B,FLCN,-0.1,87,smooth,Wnt signalling
1186,LGMD2I_B,ATF6,0.2,54,cardiac,cancer pathways
1187,LGMD2I_B,TRAFD1,-0.2,60,skeletal,propanoate metabolism
1188,LGMD2I_B,BICD1,0.3,91,cardiac,MAPK
1189,LGMD2I_B,ANP32A,NA,71,smooth,synthesis and degradation of ketone bodies
1190,LGMD2I_B,KDSR,0.1,70,skeletal,citrate cycle
1191,LGMD2I_B,FBXO9,-0.2,77,cardiac,MAPK
1192,LGMD2I_B,UBQLN2,-0.2,94,cardiac,apoptosis
1193,LGMD2I_B,ZFX,NA,10,skeletal,apoptosis
1194,LGMD2I_B,CPLX2,0.2,12,smooth,Wnt signalling
1195,LGMD2I_B,CLPX,-0.3,26,smooth,apoptosis
1196,LGMD2I_B,SGCB,-0.1,45,smooth,synthesis and degradation of ketone bodies
1197,LGMD2I_B,SEMA5A,-0.2,22,skeletal,focal adhesion
1198,LGMD2I_B,PTPRB,0.1,62,smooth,MAPK
1199,LGMD2I_B,TMEM33,0.1,34,cardiac,pyruvate metabolism
1200,LGMD2I_B,SMC1A,-0.2,89,skeletal,Wnt signalling
,,,,,,#VALUE!
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!
,,,,,,#VALUE!